Ossiam Has $4.35 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Ossiam decreased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,328 shares of the medical equipment provider’s stock after selling 1,193 shares during the period. Ossiam’s holdings in Intuitive Surgical were worth $4,347,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of ISRG. Atala Financial Inc acquired a new stake in Intuitive Surgical in the 4th quarter valued at about $25,000. Hurley Capital LLC acquired a new stake in Intuitive Surgical in the fourth quarter worth $28,000. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter worth about $26,000. BankPlus Trust Department acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $28,000. Finally, Summit Securities Group LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth about $30,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $482.74 on Friday. The company has a market capitalization of $171.94 billion, a PE ratio of 75.31, a P/E/G ratio of 5.85 and a beta of 1.55. Intuitive Surgical, Inc. has a one year low of $364.31 and a one year high of $616.00. The company has a 50-day simple moving average of $522.23 and a two-hundred day simple moving average of $532.34.

Analysts Set New Price Targets

ISRG has been the topic of a number of recent analyst reports. Leerink Partners boosted their target price on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Truist Financial dropped their price target on Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating for the company in a research note on Monday, March 17th. Bernstein Bank boosted their price target on Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. Jefferies Financial Group upped their price objective on shares of Intuitive Surgical from $475.00 to $575.00 in a research report on Monday, January 27th. Finally, Erste Group Bank downgraded Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $611.81.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the sale, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jamie Samath sold 269 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $590.00, for a total value of $158,710.00. Following the completion of the sale, the chief financial officer now owns 3,282 shares of the company’s stock, valued at approximately $1,936,380. The trade was a 7.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,754 shares of company stock valued at $17,691,621. 0.70% of the stock is owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.